PARSIPPANY, NJ – October 30, 2017 – Castle Creek Pharmaceuticals (CCP), a global company dedicated to delivering transformative therapies to patients with orphan dermatologic and other underserved conditions, today announced that Amir Tavakkol, Ph.D., has joined the company as executive vice president and chief development officer. Dr. Tavakkol will report directly to Michael Derby, co-founder and chief executive officer at CCP.

“We are pleased to welcome Dr. Tavakkol to the Castle Creek executive leadership team,” said Mr. Derby. “With nearly three decades of experience in drug development, his insights on designing and executing clinical trials and the regulatory review process will be especially valuable to us as we advance our pipeline of products into later stages of clinical development.”

Prior to joining CCP, Dr. Tavakkol served as the chief development officer at Viamet Pharmaceuticals where he led the antifungal drug development programs. He has also served as senior vice president and head of clinical development and operations at Topica Pharmaceuticals, product development team leader for antifungals at Merck & Co., senior director and head of dermatology global clinical research at Schering-Plough, director and clinical program leader and associate director of medical affairs at Novartis Pharmaceuticals, and senior research associate at Colgate-Palmolive Company. Dr. Tavakkol was a faculty member in the dermatology department at the University of Michigan where he studied the retinoid and UV effects in human skin, and he earned a Ph.D. in clinical microbiology and virology from the University of Manchester, UK.

“Throughout my career I have focused on leading clinical development and medical affairs functions that have resulted in high-impact advances in the treatment of nail, skin and hair fungal diseases,” said Dr. Tavakkol. “I look forward to using my experience managing cross functional project teams and clinical development teams in dermatology and infectious diseases to support successful regulatory filings and product launches in the exciting years ahead at Castle Creek.”

About Castle Creek Pharmaceuticals

Castle Creek Pharmaceuticals (CCP), a member of the Paragon Biosciences corporate family, is a privately held biopharmaceutical company with a robust and diversified pipeline of late-stage products. The company business strategy is based on a demonstrated ability to identify and advance therapies backed by strong science with the potential to represent significant advances in the treatment of debilitating dermatologic and head and neck conditions with high unmet needs. For more information, please visit